Cardiac safety of ophthalmic timolol

References

• Quigley HA. Glaucoma. Lancet. 2011;377:1367–1377.
   PubMed Web of Science ®Google Scholar
• Schmidl D, Schmetterer L, Garhofer G, et al. Pharmacotherapy of glaucoma. J Ocul Pharmacol Ther. 2015;31:63–77.
   PubMed Web of Science ®Google Scholar
• Reiter MJ. Cardiovascular drug class specificity: beta-blockers. Prog Cardiovasc Dis. 2004;47:11–33.
   PubMed Web of Science ®Google Scholar
• Brayfield A, editor. Timolol maleate. Martindale: The Complete Drug Reference. London: Pharmaceutical Press; [cited 2016 Apr 16]. Available from: http://www.medicinescomplete.com/
   Google Scholar
• Craiglow BG, Antaya RJ. Management of infantile hemangiomas: current and potential pharmacotherapeutic approaches. Pediatr Drugs. 2013;15:133–138.
   PubMed Web of Science ®Google Scholar
• Raphael MF, Breur JM, Vlasveld FA, et al. Treatment of infantile hemangiomas: therapeutic options in regard to side effects and adverse events - a review of the literature. Expert Opin Drug Saf. 2016;15:199–214.
   PubMed Web of Science ®Google Scholar
• Grieshaber MC, Flammer J. Is the medication used to achieve the target intraocular pressure in glaucoma therapy of relevance?–an exemplary analysis on the basis of two beta-blockers. Prog Retin Eye Res. 2010;29:79–93.
   PubMed Web of Science ®Google Scholar
• European Glaucoma Society (EGS). Terminology and guidelines for glaucoma. 4th ed. Savona: Publicomm S.r.l.; 2014 [cited 2016 Apr 10]. Chapter 3.3, Antiglaucoma drugs; p. 140–158. Available from: http://www.eugs.org/eng/egs_guidelines_reg.asp?l=1
   Google Scholar
• Nelson WL, Fraunfelder FT, Sills JM, et al. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978–1985. Am J Ophthalmol. 1986;102:606–611.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Pharmacovigilance Working Party (PhVWP), monthly report. Annex 1: summary assessment report; beta-blockers for ophthalmic use – risk of systemic adverse reactions. 2011 Jun 30 [cited 2016 Apr 16]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/06/WC500108098.pdf?_sm_au_=ikV30Vt5QQDN1Stc
   Google Scholar
• Sharifi M, Koch JM, Steele RJ, et al. Third degree AV block due to ophthalmic timolol solution. Int J Cardiol. 2001;80:257–259.
   PubMed Web of Science ®Google Scholar
• Minish T, Herd A. Symptomatic bradycardia secondary to interaction between topical timolol maleate, verapamil, and flecainide: a case report. J Emerg Med. 2002;22:247–249.
   PubMed Web of Science ®Google Scholar
• van der Velde N, Ziere G, van der Cammen TJM. Falls in three patients due to timolol eye drops, tolterodine, and flecainide. J Gerontol A Biol Sci Med Sci. 2004;59:1343–1344.
   PubMed Web of Science ®Google Scholar
• Carey BJ. Atishoo! Atishoo! We all fall down!. Age Ageing. 2006;35:446–447.
   PubMed Web of Science ®Google Scholar
• Müller ME, van der Velde N, Krulder JW, et al. Syncope and falls due to timolol eye drops. BMJ. 2006;332:960–961.
   PubMed Web of Science ®Google Scholar
• Calenda E, Tourrel F. Sinoatrial block induced by timolol eyedrops. Can J Ophthalmol. 2007;42:149.
   PubMed Web of Science ®Google Scholar
• Patane’ S, Marte F, Di Bella G, et al. Atrial fibrillation, pharmacological cardioversion and topical ophthalmic beta-blocker use. Int J Cardiol. 2008;126:e43–e46.
   Google Scholar
• Walia HS, Walia SS, Emanuel ME. Sick sinus syndrome associated with topical timolol maleate instillation. J Pharmacol Pharmacother. 2011;2:300–302.
   PubMedGoogle Scholar
• Canpolat U, Gurses KM, Aytemir K, et al. Severe bradycardia and syncope due to topical ophthalmic timolol. Herz. 2013;38:556–557.
   PubMed Web of Science ®Google Scholar
• Lee L, Turnbull C, Akhtar MM, et al. Ganfort, a blinding drug to the physician. BMJ Case Reports. 2012 [cited 2012 Sep 7]. doi:10.1136/bcr.01.2012.5648.
   Google Scholar
• Mäenpää J. Pharmacology of ophthalmic drugs. In: Pelkonen O, Ruskoaho H, Hakkola J, editors. Medical pharmacology and toxicology. Helsinki: Duodecim Medical Publications Ltd.; 2014. p. 973–984. Finnish
   Google Scholar
• Lee AJ, Wang JJ, Kifley A, et al. Open-angle glaucoma and cardiovascular mortality: the Blue Mountains Eye Study. Ophthalmology. 2006;113:1069–1076.
   PubMed Web of Science ®Google Scholar
• Wu S-Y, Nemesure B, Hennis A, et al. Open-angle glaucoma and mortality: the barbados eye studies. Arch Ophthalmol. 2008;126:365–370.
   PubMedGoogle Scholar
• Lama PJ. Topical β-adrenergic blockers and glaucoma: a heart-stopping association? Ophthalmology. 2006;113:1067–1068.
   PubMed Web of Science ®Google Scholar
• Vogler J, Breithardt G, Eckardt L. Bradyarrhythmias and conduction blocks. Rev Esp Cardiol (Engl Ed). 2012;65:656–667.
   PubMed Web of Science ®Google Scholar
• Dickstein K, Hapnes R, Aarsland T. Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma. Am J Ophthalmol. 2001;132:626–632.
   PubMed Web of Science ®Google Scholar
• Dinai Y, Sharir M, Naveh N, et al. Bradycardia induced by interaction between quinidine and ophthalmic timolol. Ann Intern Med. 1985;103:890–891.
   PubMed Web of Science ®Google Scholar
• Pringle SD, MacEwen CJ. Severe bradycardia due to interaction of timolol eye drops and verapamil. Br Med J (Clin Res Ed). 1987;294:155–156.
   PubMed Web of Science ®Google Scholar
• Tattersall C, Vernon S, Singh R. Resting pulse rates in a glaucoma clinic: the effect of topical and systemic beta-blocker usage. Eye (Lond). 2006;20:221–225.
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Kähönen M, Ropo A, et al. Improved systemic safety and risk-benefit ratio of topical 0.1% timolol hydrogel compared with 0.5% timolol aqueous solution in the treatment of glaucoma. Graefes Arch Clin Exp Ophthalmol. 2006;244:1491–1496.
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Niño J, Tahvanainen K, et al. Efficacy and systemic side-effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel. Acta Ophthalmol Scand. 2005;83:723–728.
   PubMedGoogle Scholar
• Pratt NL, Ramsay EN, Kalisch Ellett LM, et al. Association between ophthalmic timolol and hospitalisation for bradycardia. J Ophthalmol. 2015 [cited 2015 Mar 22]. doi:10.1155/2015/567387.
   PubMed Web of Science ®Google Scholar
• Logan IC, Witham MD. Efficacy of treatments for orthostatic hypotension: a systematic review. Age Ageing. 2012;41:587–594.
   PubMed Web of Science ®Google Scholar
• Niño J, Tahvanainen K, Uusitalo H, et al. Cardiovascular effects of ophthalmic 0.5% timolol aqueous solution and 0.1% timolol hydrogel. Clin Physiol Funct Imaging. 2002;22:271–278.
   PubMed Web of Science ®Google Scholar
• Kannus P, Sievänen H, Palvanen M, et al. Prevention of falls and consequent injuries in elderly people. Lancet. 2005;366:1885–1893.
   PubMed Web of Science ®Google Scholar
• Glynn RJ, Seddon JM, Krug JH, et al. Falls in elderly patients with glaucoma. Arch Ophthalmol. 1991;109:205–210.
   PubMed Web of Science ®Google Scholar
• Ham AC, Swart KMA, Enneman AW, et al. Medication-related fall incidents in an older, ambulant population: the B-PROOF study. Drugs Aging. 2014;31:917–927.
   PubMed Web of Science ®Google Scholar
• DuoTrav 40 micrograms/mL + 5 mg/mL eye drops, solution. Summary of product characteristics (UK). [ cited 2016 Apr 17]. Available from: https://www.medicines.org.uk/emc/medicine/17774
   Google Scholar
• Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol. 2010;4:1–9.
   PubMedGoogle Scholar
• Holló G, Vuorinen J, Tuominen J, et al. Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products. Adv Ther. 2014;31:932–944.
   PubMed Web of Science ®Google Scholar
• Kaarniranta K, Ikäheimo K, Mannermaa E, et al. Pharmacokinetics, efficacy, and safety of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in healthy volunteers: a phase I comparison vs. the corresponding preservative-free monotherapies. Clin Pharmacokinet. 2016;55:485–494.
   PubMed Web of Science ®Google Scholar
• Saini P, Loke YK, Gamble C, et al. Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. BMJ. 2014 [cited 2014 Nov 21]. doi:10.1136/bmj.g6501.
   Web of Science ®Google Scholar
• Higginbotham EJ. Topical beta-adrenergic antagonists and quinidine. A risky interaction. Arch Ophthalmol. 1996;114:745–746.
   PubMedGoogle Scholar
• Spratt A, Ogunbowale L, Wormald R, et al. What’s in a name? New glaucoma drugs. Lancet. 2006;368:826–827.
   PubMed Web of Science ®Google Scholar
• Nieminen T, Uusitalo H, Turjanmaa V, et al. Association between low plasma levels of ophthalmic timolol and haemodynamics in glaucoma patients. Eur J Clin Pharmacol. 2005;61:369–374.
   PubMed Web of Science ®Google Scholar
• Mäenpää J, Volotinen-Maja M, Kautiainen H, et al. Paroxetine markedly increases plasma concentrations of ophthalmic timolol; CYP2D6 inhibitors may increase the risk of cardiovascular adverse effects of 0.5% timolol eye drops. Drug Metab Dispos. 2014;42:2068–2076.
   PubMed Web of Science ®Google Scholar
• Ghate D, Edelhauser HF. Barriers to glaucoma drug delivery. J Glaucoma. 2008;17:147–156.
   PubMed Web of Science ®Google Scholar
• Sakanaka K, Kawazu K, Nishida K, et al. Transport of timolol and tilisolol in rabbit corneal epithelium. Biol Pharm Bull. 2006;29:2143–2147.
   PubMed Web of Science ®Google Scholar
• Volotinen M, Mäenpää J, Kautiainen K, et al. Ophthalmic timolol in a hydrogel vehicle leads to minor inter-individual variation in timolol concentration in aqueous humor. Eur J Pharm Sci. 2009;36:292–296.
   PubMed Web of Science ®Google Scholar
• Volotinen M, Turpeinen M, Tolonen A, et al. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. Drug Metab Dispos. 2007;35:1135–1141.
   PubMed Web of Science ®Google Scholar
• Zhang T, Xiang CD, Gale D, et al. Drug transporter and cytochrome P450 mRNA expression in human ocular barriers: implications for ocular drug disposition. Drug Metab Dispos. 2008;36:1300–1307.
   PubMed Web of Science ®Google Scholar
• Volotinen M, Mäenpää J, Kankuri E, et al. Expression of cytochrome P450 (CYP) enzymes in human nonpigmented ciliary epithelial cells: induction of CYP1B1 expression by TCDD. Invest Ophthalmol Vis Sci. 2009;50:3099–3105.
   PubMed Web of Science ®Google Scholar
• Volotinen M, Hakkola J, Pelkonen O, et al. Metabolism of ophthalmic timolol: new aspects of an old drug. Basic Clin Pharmacol Toxicol. 2011;108:297–303.
   PubMed Web of Science ®Google Scholar
• Korte JM, Kaila T, Saari KM. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefes Arch Clin Exp Ophthalmol. 2002;240:430–435.
   PubMed Web of Science ®Google Scholar
• Goldberg I, Moloney G, McCluskey P. Topical ophthalmic medications: what potential for systemic side effects and interactions with other medications? Med J Aust. 2008;189:356–357.
   PubMed Web of Science ®Google Scholar
• Nieminen T, Lehtimäki T, Mäenpää J, et al. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scand J Clin Lab Invest. 2007;67:237–245.
   PubMed Web of Science ®Google Scholar
• Tocco DJ, Duncan AE, deLuna FA, et al. Timolol metabolism in man and laboratory anamals. Drug Metab Dispos. 1980;8:236–240.
   PubMed Web of Science ®Google Scholar
• Fourtillan JB, Courtois P, Lefebvre MA, et al. Pharmacokinetics of oral timolol studied by mass fragmentography. Eur J Clin Pharmacol. 1981;19:193–196.
   PubMed Web of Science ®Google Scholar
• Volotinen M, Korjamo T, Tolonen A, et al. Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. Basic Clin Pharmacol Toxicol. 2010;106:302–309.
   PubMed Web of Science ®Google Scholar
• Bertelsen KM, Venkatakrishnan K, Von Moltke LL, et al. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos. 2003;31:289–293.
   PubMed Web of Science ®Google Scholar
• Liu X-L, Jia Q-J, Wang L-N, et al. Roles of CYP2C19 gene polymorphisms in susceptibility to POAG and individual differences in drug treatment response. Med Sci Monit. 2016;22:310–315.
   PubMedGoogle Scholar
• Yamamoto T, Suzuki A, Kohno Y. High-throughput screening to estimate single or multiple enzymes involved in drug metabolism: microtitre plate assay using a combination of recombinant CYP2D6 and human liver microsomes. Xenobiotica. 2003;33:823–839.
   PubMed Web of Science ®Google Scholar
• Pelkonen O, Turpeinen M, Hakkola J, et al. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol. 2008;82:667–715.
   PubMed Web of Science ®Google Scholar
• Pelkonen O, Mäenpää J, Taavitsainen P, et al. Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998;28:1203–1253.
   PubMed Web of Science ®Google Scholar
• Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet. 2009;48:689–723.
   PubMed Web of Science ®Google Scholar
• Alvan G, von Bahr C, Seidemann P, et al. High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation. Lancet. 1982;1:333.
   PubMed Web of Science ®Google Scholar
• Lewis RV, Lennard MS, Jackson PR, et al. Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol. 1985;19:329–333.
   PubMed Web of Science ®Google Scholar
• McGourty JC, Silas JH, Fleming JJ, et al. Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin. Clin Pharmacol Ther. 1985;38:409–413.
   PubMed Web of Science ®Google Scholar
• Alvan G, Calissendorff B, Seideman P, et al. Absorption of ocular timolol. Clin Pharmacokinet. 1980;5:95–100.
   PubMed Web of Science ®Google Scholar
• Edeki TI, He H, Wood AJ. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction. JAMA. 1995;274:1611–1613.
   PubMed Web of Science ®Google Scholar
• Nieminen T, Uusitalo H, Mäenpää J, et al. Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. Eur J Clin Pharmacol. 2005;61:811–819.
   PubMed Web of Science ®Google Scholar
• Leeder JS, Gaedigk A. CYP2D6 and pharmacogenomics: where does future research need to focus? Part 2: clinical aspects. Pharmacogenomics. 2014;15:1055–1058.
   PubMed Web of Science ®Google Scholar
• Kaila T, Huupponen R, Karhuvaara S, et al. Beta-blocking effects of timolol at low plasma concentrations. Clin Pharmacol Ther. 1991;49:53–58.
   PubMed Web of Science ®Google Scholar
• Haefeli WE, Bargetzi MJ, Follath F, et al. Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo. J Cardiovasc Pharmacol. 1990;15:776–779.
   PubMed Web of Science ®Google Scholar
• Labbe L, O’Hara, G, Lefebvre M, et al. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings. Clin Pharmacol Ther. 2000;68:44–57.
   PubMed Web of Science ®Google Scholar
• Ishii Y, Nakamura K, Tsutsumi K, et al. Drug interaction between cimetidine and timolol ophthalmic solution: effect on heart rate and intraocular pressure in healthy Japanese volunteers. J Clin Pharmacol. 2000;40:193–199.
   PubMed Web of Science ®Google Scholar
• Almenoff JS, DuMouchel W, Kindman LA, et al. Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting. Pharmacoepidemiol Drug Saf. 2003;12:517–521.
   PubMed Web of Science ®Google Scholar
• Goldberg I, Adena MA. Co-prescribing of topical and systemic beta-blockers in patients with glaucoma: a quality use of medicine issue in Australian practice. Clin Experiment Ophthalmol. 2007;35:700–705.
   PubMed Web of Science ®Google Scholar
• Brauner SC, Chen TC, Hutchinson BT, et al. The course of glaucoma during pregnancy: a retrospective case series. Arch Ophthalmol. 2006;124:1089–1094.
   PubMedGoogle Scholar
• Mendez-Hernandez C, Garcia-Feijoo J, Saenz-Frances F, et al. Topical intraocular pressure therapy effects on pregnancy. Clin Ophthalmol. 2012;6:1629–1632.
   PubMedGoogle Scholar
• Wagenvoort AM, Van Vugt JM, Sobotka M, et al. Topical timolol therapy in pregnancy: is it safe for the fetus? Teratology. 1998;58:258–262.
   PubMedGoogle Scholar
• Hakkola J, Pasanen M, Purkunen R, et al. Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver. Biochem Pharmacol. 1994;48:59–64.
   PubMed Web of Science ®Google Scholar
• Stevens JC, Marsh SA, Zaya MJ, et al. Developmental changes in human liver CYP2D6 expression. Drug Metab Dispos. 2008;36:1587–1593.
   PubMed Web of Science ®Google Scholar
• Johnson SM, Martinez M, Freedman S. Management of glaucoma in pregnancy and lactation. Surv Ophthalmol. 2001;45:449–454.
   PubMed Web of Science ®Google Scholar
• Bussières J-F, Therrien R, Hamel P, et al. Retrospective cohort study of 163 pediatric glaucoma patients. Can J Ophthalmol. 2009;44:323–327.
   PubMed Web of Science ®Google Scholar
• Samant M, Medsinge A, Nischal KK. Pediatric glaucoma: pharmacotherapeutic options. Pediatr Drugs. 2016;18:209–219.
   PubMed Web of Science ®Google Scholar
• Passo MS, Palmer EA, Van Buskirk EM, et al. Plasma timolol in glaucoma patients. Ophthalmology. 1984;91:1361–1363.
   PubMed Web of Science ®Google Scholar
• Mungan NK, Wilson TW, Nischal KK, et al. Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers. J AAPOS. 2003;7:69–70.
   PubMed Web of Science ®Google Scholar
• Kiryazov K, Stefova M, Iotova V, et al. Can ophthalmic drops cause central nervous system depression and cardiogenic shock in infants? Pediatr Emerg Care. 2013;29:1207–1209.
   PubMed Web of Science ®Google Scholar
• Weibel L, Barysch M, Scheer HS, et al. Topical timolol: evidence for efficacy and degree of systemic absorption. Pediatr Dermatol. 2016;33:184–190.
   PubMed Web of Science ®Google Scholar
• Huber M, Kölzsch M, Stahlmann R, et al. Ophthalmic drugs as part of polypharmacy in nursing home residents with glaucoma. Drugs Aging. 2013;30:31–38.
   PubMed Web of Science ®Google Scholar
• Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41:67–76.
   PubMed Web of Science ®Google Scholar
• Timoptol® 0.25%/0.5% w/v eye drops solution. Summary of product characteristics (UK). [ cited 2016 Apr 17]. Available from: https://www.medicines.org.uk/emc/medicine/31332
   Google Scholar